Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes

Kelly E. Craven, Jesse Gore, Julie L. Wilson, Murray Korc

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinomas (PDACs) are hypovascular, but overexpress pro-angiogenic factors and exhibit regions of microvasculature. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we previously reported that ~12% of PDACs have an angiogenesis gene signature with increased expression of multiple pro-angiogenic genes. By analyzing the recently expanded TCGA dataset, we now report that this signature is present in ~35% of PDACs but that it is mostly distinct from an angiogenesis signature present in pancreatic neuroendocrine tumors (PNETs). These PDACs exhibit a transcriptome that reflects active TGF-β signaling, and up-regulation of several pro-inflammatory genes, and many members of JAK signaling pathways. Moreover, expression of SMAD4 and HDAC9 correlates with endothelial cell abundance in PDAC tissues. Concomitantly targeting the TGF-β type I receptor (TβRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs. By contrast, either inhibitor alone does not suppress their enhanced proliferation in 3D co-cultures. These findings suggest that targeting both TGF-β and JAK1 signaling could be explored therapeutically in the 35% of PDAC patients whose cancers exhibit an angiogenesis gene signature.

Original languageEnglish (US)
Pages (from-to)323-341
Number of pages19
JournalOncotarget
Volume7
Issue number1
DOIs
StatePublished - Jan 5 2016

Fingerprint

Pancreatic Neoplasms
Transcriptome
Transforming Growth Factor beta
Adenocarcinoma
Genes
Endothelial Cells
Atlases
Genome
Neoplasms
Neuroendocrine Tumors
Angiogenesis Inducing Agents
Coculture Techniques
Microvessels
Phosphotransferases
Up-Regulation
Phosphorylation
RNA

Keywords

  • angiogenesis
  • inflammation
  • pancreatic cancer
  • TCGA
  • TGF-β

ASJC Scopus subject areas

  • Oncology

Cite this

Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. / Craven, Kelly E.; Gore, Jesse; Wilson, Julie L.; Korc, Murray.

In: Oncotarget, Vol. 7, No. 1, 05.01.2016, p. 323-341.

Research output: Contribution to journalArticle

Craven, Kelly E. ; Gore, Jesse ; Wilson, Julie L. ; Korc, Murray. / Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. In: Oncotarget. 2016 ; Vol. 7, No. 1. pp. 323-341.
@article{c988f32495de448d8bbba1828aa181e0,
title = "Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes",
abstract = "Pancreatic ductal adenocarcinomas (PDACs) are hypovascular, but overexpress pro-angiogenic factors and exhibit regions of microvasculature. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we previously reported that ~12{\%} of PDACs have an angiogenesis gene signature with increased expression of multiple pro-angiogenic genes. By analyzing the recently expanded TCGA dataset, we now report that this signature is present in ~35{\%} of PDACs but that it is mostly distinct from an angiogenesis signature present in pancreatic neuroendocrine tumors (PNETs). These PDACs exhibit a transcriptome that reflects active TGF-β signaling, and up-regulation of several pro-inflammatory genes, and many members of JAK signaling pathways. Moreover, expression of SMAD4 and HDAC9 correlates with endothelial cell abundance in PDAC tissues. Concomitantly targeting the TGF-β type I receptor (TβRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs. By contrast, either inhibitor alone does not suppress their enhanced proliferation in 3D co-cultures. These findings suggest that targeting both TGF-β and JAK1 signaling could be explored therapeutically in the 35{\%} of PDAC patients whose cancers exhibit an angiogenesis gene signature.",
keywords = "angiogenesis, inflammation, pancreatic cancer, TCGA, TGF-β",
author = "Craven, {Kelly E.} and Jesse Gore and Wilson, {Julie L.} and Murray Korc",
year = "2016",
month = "1",
day = "5",
doi = "10.18632/oncotarget.6345",
language = "English (US)",
volume = "7",
pages = "323--341",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes

AU - Craven, Kelly E.

AU - Gore, Jesse

AU - Wilson, Julie L.

AU - Korc, Murray

PY - 2016/1/5

Y1 - 2016/1/5

N2 - Pancreatic ductal adenocarcinomas (PDACs) are hypovascular, but overexpress pro-angiogenic factors and exhibit regions of microvasculature. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we previously reported that ~12% of PDACs have an angiogenesis gene signature with increased expression of multiple pro-angiogenic genes. By analyzing the recently expanded TCGA dataset, we now report that this signature is present in ~35% of PDACs but that it is mostly distinct from an angiogenesis signature present in pancreatic neuroendocrine tumors (PNETs). These PDACs exhibit a transcriptome that reflects active TGF-β signaling, and up-regulation of several pro-inflammatory genes, and many members of JAK signaling pathways. Moreover, expression of SMAD4 and HDAC9 correlates with endothelial cell abundance in PDAC tissues. Concomitantly targeting the TGF-β type I receptor (TβRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs. By contrast, either inhibitor alone does not suppress their enhanced proliferation in 3D co-cultures. These findings suggest that targeting both TGF-β and JAK1 signaling could be explored therapeutically in the 35% of PDAC patients whose cancers exhibit an angiogenesis gene signature.

AB - Pancreatic ductal adenocarcinomas (PDACs) are hypovascular, but overexpress pro-angiogenic factors and exhibit regions of microvasculature. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we previously reported that ~12% of PDACs have an angiogenesis gene signature with increased expression of multiple pro-angiogenic genes. By analyzing the recently expanded TCGA dataset, we now report that this signature is present in ~35% of PDACs but that it is mostly distinct from an angiogenesis signature present in pancreatic neuroendocrine tumors (PNETs). These PDACs exhibit a transcriptome that reflects active TGF-β signaling, and up-regulation of several pro-inflammatory genes, and many members of JAK signaling pathways. Moreover, expression of SMAD4 and HDAC9 correlates with endothelial cell abundance in PDAC tissues. Concomitantly targeting the TGF-β type I receptor (TβRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs. By contrast, either inhibitor alone does not suppress their enhanced proliferation in 3D co-cultures. These findings suggest that targeting both TGF-β and JAK1 signaling could be explored therapeutically in the 35% of PDAC patients whose cancers exhibit an angiogenesis gene signature.

KW - angiogenesis

KW - inflammation

KW - pancreatic cancer

KW - TCGA

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=85021858471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021858471&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6345

DO - 10.18632/oncotarget.6345

M3 - Article

VL - 7

SP - 323

EP - 341

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -